REGENTIS BIOMATERIALS LTD. (RGNT) Form 6-K — Sep 11, 2026
Regentis Biomaterials reported a first half 2026 net loss of approximately $2.6 million, or $0.44 per share, improved from a $3.2 million loss a year earlier, with cash of approximately $9.0 million at June 30, 2026 after a $6.5 million June private placement and full repayment of its short-term debt. The company advanced its pivotal U.S. Phase III trial of GelrinC with 43 of 80 patients treated and now expects full enrollment around the end of 2026, later than its prior third-quarter target, while expanding European commercial preparation and winning regulatory approval of a new manufacturing process that improves production yield by 400%.
Key figures
- Total Debt
- 0
- Total Assets
- 9350000
- Cash Position
- 8952000
- Gross Proceeds
- 6500000
- Offering Price
- 3.5
- Shares Offered
- 1844543
- Shares Outstanding
- 7023921
- Period
- six months ended June 30, 2026
- Ga expense
- $1.2 million vs $259,000 in H1 2025 (+362%)
- Rd expense
- $1.2 million vs $180,000 in H1 2025 (+568%)
- Cash runway
- through September 2027
- Ipo dec 2025
- 1,250,000 shares at $8.00; ~$10 million gross, ~$8.0 million net
- Operating loss
- $2.4 million vs $439,000 in H1 2025
- Accumulated deficit
- $58.4 million
- Prior year net loss
- -$3.2 million (-$1.17 per share)
- Us market opportunity
- ~470,000 cartilage knee repair cases annually
- Private placement terms
- $3.50 per ordinary share plus ordinary warrant ($4.20 exercise, 5-year); June 2026
- Pivotal trial enrollment
- 43 of 80 patients treated; full enrollment expected around year end 2026 (previously third quarter)
- Iia contingent obligation
- ~$2.61 million including ~$300 thousand interest
- Net cash used in operations
- $2.8 million in H1 2026
- Production yield improvement
- 400%
- Operating tax loss carryforwards
- $53 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.